ICLR
ICONCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The best near-term bull read is that the core franchise may be intact despite the accounting failure: management said there was no customer, operational, or cash-flow impact, the quantified overstatement was below the prior 2% ceiling, and the stock's April 29 relief move suggests investors were positioned for worse.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +30.4.
What can break
Form 20-F has not yet been filed; management only guided to completion in the coming weeks.
Momentum
65
Value
69
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $108.00 · Bull $125.00 · Bear $85.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $132.27
Why
Momentum65 · Δ7d +30.4
Value69 · Δ7d -0.8
Sentiment25 · Δ7d -11.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
65
34% active weight
Current posture
7d trendImproving
Δ7d
+30.4
Δ21d
+36.0
Value
69
32% active weight
Current posture
7d trendFlat
Δ7d
-0.8
Δ21d
-0.3
Sentiment
25
33% active weight
Current posture
7d trendSoftening
Δ7d
-11.6
Δ21d
-5.6
Why this grade
Composite grade C. Momentum 65.5 / Value 68.8 / Sentiment 25.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$10.53B
Beta
1.27
Shares Out
76.36M
P/E (TTM)
26.7
P/S (TTM)
1.86
P/FCF (TTM)
15.65
Rev YoY
+0.6%
EPS YoY
-98.7%
Gross Margin
+28.2%
Op Margin
+10.0%
Net Debt
$2.89B
Current Ratio
1.06
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology